DEF: Dyne Therapeutics Sets Date for 2025 Annual Stockholders Meeting, Outlines Key Proposals

Dyne Therapeutics announces its 2025 Annual Meeting of Stockholders to be held virtually on May 30, 2025, featuring director elections, executive compensation votes, and auditor ratification.

Summary

• Dyne Therapeutics will hold its 2025 Annual Meeting of Stockholders virtually on May 30, 2025, at 11:00 a.m. Eastern Time.
• Stockholders of record as of April 4, 2025, are entitled to vote on several key proposals.
• The proposals include the election of Edward Hurwitz and Dirk Kersten as Class II directors for a three-year term expiring in 2028.
• An advisory vote will be held to approve the compensation of the named executive officers.
• Stockholders will also vote on the frequency of future advisory votes on executive compensation.
• The appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, will be ratified.
• The board of directors recommends voting FOR the election of directors, FOR the approval of executive compensation, FOR holding advisory votes on executive compensation every 1 YEAR, and FOR the ratification of the auditor appointment.
• Proxy materials and the 2024 Annual Report are available online at www.proxydocs.com/DYN.
• Stockholders can request paper copies of these documents by May 17, 2025.
• The company's board consists of seven members divided into three classes with staggered three-year terms.
• The board has determined that all directors, except for the CEO John G. Cox, are independent under Nasdaq rules.
• The company has adopted corporate governance guidelines, committee charters, and a code of business conduct and ethics, all available on its website.
• The compensation committee approved 2024 salary increases for Mr. Brumm, Dr. Beskrovnaya and Mr. Scalzo.
• The 2024 base salary for each of Mr. Cox, Ms. Friedl-Naderer and Dr. Kerr were set pursuant to the terms of their offer letters entered into in March 2024, June 2024 and July 2024, respectively.
• The compensation committee set the target bonus opportunity for Mr. Cox at 60%, Mr. Brumm at 55%, Mr. Scalzo at 35%, Dr. Beskrovnaya at 40%, Ms. Friedl-Naderer at 40% and Dr. Kerr at 40%.
• The compensation committee determined a corporate performance score of 105% to be used for purposes of calculating 2024 bonus payments.
• The compensation committee determined that the mix for the 2024 annual equity grants to our NEOs be split 50% in stock options and 50% in RSUs, based on grant date value.
• The company has adopted a Dodd-Frank Compensation Recovery Policy, or Clawback Policy, effective as of November 21, 2023.
• The company has entered into employee invention and non-disclosure agreements and non-competition and non-solicitation agreements with each of our NEOs.

Sentiment

Score: 7

Explanation: The document is primarily informational, outlining meeting details and governance procedures. The sentiment is neutral to slightly positive due to the focus on future growth and development.

Positives

• The company is providing stockholders with multiple avenues to participate in the Annual Meeting, including online attendance and voting.
• The board of directors is actively engaged in risk oversight, ensuring the company is managed for the long-term benefit of stockholders.
• The company has adopted corporate governance guidelines, committee charters, and a code of business conduct and ethics to ensure good corporate governance.
• The company has adopted a Dodd-Frank Compensation Recovery Policy, or Clawback Policy, effective as of November 21, 2023.
• The company has entered into employee invention and non-disclosure agreements and non-competition and non-solicitation agreements with each of our NEOs.

Risks

• The outcome of the advisory vote on executive compensation is non-binding, meaning the board may decide to compensate executives differently than approved by stockholders.
• The company faces a number of risks, including those described under the caption Risk Factors in our 2024 Annual Report.

Future Outlook

The company is preparing for potential U.S. Accelerated Approval in the first half of 2026 for DYNE-101 and in early 2026 for DYNE-251 and future commercialization.

Industry Context

The document provides insight into the corporate governance practices and executive compensation strategies within the biotechnology industry, particularly for companies focused on neuromuscular diseases.

Comparison to Industry Standards

• The compensation committee compares our executive compensation against a peer group of companies.
• The compensation committee also annually reviews the executive pay practices of other similarly situated companies as reported by Compensia through the survey data reported by the Radford Global Life Sciences Survey.

Management Changes

Related Party Transactions

• Atlas Venture and related affiliated entities purchased an aggregate of 1,111,111 shares of our common stock at a purchase price of $13.50 per share.
• Entities affiliated with Forbion Capital Fund IV Cooperatief U.A. purchased an aggregate of 1,714,285 shares of our common stock in the public offering.
• Deep Track Capital, L.P. purchased 1,500,000 shares of common stock in the January 2024 public offering.

Stakeholder Impact

• The proposals outlined in the proxy statement directly impact shareholders, who have the opportunity to vote on key decisions regarding the company's governance and executive compensation.
• Executive compensation decisions impact employees, particularly executive officers, by determining their remuneration and incentives.
• The selection of an independent auditor affects the reliability of financial reporting, which is important for investors, creditors, and other stakeholders.

Next Steps

• Stockholders are encouraged to read the proxy statement and submit their proxy or voting instructions as soon as possible.
• Stockholders wishing to suggest a candidate for director should write to our Corporate Secretary.
• The company will file final voting results in a current report on Form 8-K with the SEC within four business days after the Annual Meeting.

Key Dates

Keywords

annual meeting, proxy statement, stockholders, directors, executive compensation, Deloitte & Touche, corporate governance, equity compensation, risk management, Dyne Therapeutics